Report Detail
Global PD-1/PD-L1 Checkpoint Inhibitors Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4734663 |
- 24 August, 2026 |
- Global |
- 104 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global PD-1/PD-L1 Checkpoint Inhibitors market size was valued at US$ 59840 million in 2025 and is forecast to a readjusted size of US$ 122780 million by 2032 with a CAGR of 10.9% during review period.
PD-1/PD-L1 checkpoint inhibitors are a class of immuno-oncology therapies designed to block the immune-suppressive signaling pathway that tumors exploit to deactivate T-cell–mediated antitumor immunity. These agents address the unmet need of patients whose tumors are resistant or poorly responsive to conventional chemotherapy and targeted therapies. The concept emerged as researchers uncovered how malignant cells overexpress PD-L1 or engage PD-1 on T cells to evade immune surveillance; the development of monoclonal antibodies capable of binding and blocking these proteins led to a therapeutic breakthrough, with the first approvals in 2014 reshaping cancer treatment worldwide. Their development and manufacturing rely on an upstream supply chain that includes cell line development materials, recombinant protein expression systems, culture media, buffers, filtration consumables, bioreactors, and aseptic filling components. This also covers nucleic acid materials for antibody engineering, analytical reagents, and instrumentation essential for quality control, forming a comprehensive upstream ecosystem that ensures product consistency, safety, and clinical performance. In 2024, global sales of PD-1/PD-L1 checkpoint inhibitors reached 28.64 million vials, with an average price of USD 1,850 per vial, and corporate gross profit margins ranging between 60% and 70%.
From a market perspective, the PD-1/PD-L1 inhibitor landscape has transitioned from a narrow set of indications to a broad, heterogeneous adoption across cancer types and treatment lines, accompanied by an increasingly crowded supplier ecosystem. Market dynamics are shaped not only by competing products but also by a growing ancillary industry of diagnostic developers, contract manufacturers and service providers that support clinical translation and commercialization. Regional differences in clinical guidelines, payer policies and healthcare infrastructure further lead to heterogeneous uptake patterns, even as overall clinical familiarity and guideline inclusion continue to strengthen usage.
Looking ahead, two complementary trends will dominate: precision immunotherapy and rational combinations. Precision approaches that integrate tumor genomics, immune microenvironment profiling and predictive biomarkers will refine patient selection and improve benefit–risk ratios, while combination regimens aim to broaden responder populations and delay or overcome resistance. Concurrently, platform innovations — such as engineered antibodies, bispecific constructs, long-acting formats and localized delivery systems — will diversify the therapeutic toolbox and open niche application opportunities.
Key growth drivers include persistent unmet clinical needs, robust R&D funding, and evolving regulatory frameworks that increasingly accommodate breakthrough immunotherapies; clinician experience and patient advocacy also accelerate adoption. Major constraints remain: intrinsic and acquired resistance in certain tumor types, uneven access driven by cost and reimbursement variability, and the high technical and capital barriers of biologics development and manufacturing. The interplay among scientific advances, payer decisions and real-world evidence generation will determine how rapidly and equitably these therapies diffuse into broader oncology practice.
This report is a detailed and comprehensive analysis for global PD-1/PD-L1 Checkpoint Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global PD-1/PD-L1 Checkpoint Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PD-1/PD-L1 Checkpoint Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PD-1/PD-L1 Checkpoint Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PD-1/PD-L1 Checkpoint Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-1/PD-L1 Checkpoint Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-1/PD-L1 Checkpoint Inhibitors market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myers Squibb, Merck, Regeneron Pharmaceuticals, Roche, Pfizer, AstraZeneca, Hengrui Pharmaceuticals, Junshi Biosciences, Innovent, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
PD-1/PD-L1 Checkpoint Inhibitors market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
Market segment by Product Name
Pembrolizumab
Nivolumab
Cemiplimab
Toripalimab
Sintilimab
Tislelizumab
Camrelizumab
Penpulimab
Retifanlimab
Zimberelimab
Atezolizumab
Durvalumab
Avelumab
Envafolimab
Adebrelimab
Market segment by Dosage Strength
100 mg / Vial
200 mg / Vial
240 mg / Vial
300 mg / Vial
Market segment by Application
Squamous Cell Skin Cancer
Non-small Cell Lung Cancer
Melanoma
Gastric Cancer
Other
Major players covered
Bristol Myers Squibb
Merck
Regeneron Pharmaceuticals
Roche
Pfizer
AstraZeneca
Hengrui Pharmaceuticals
Junshi Biosciences
Innovent
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PD-1/PD-L1 Checkpoint Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, with price, sales quantity, revenue, and global market share of PD-1/PD-L1 Checkpoint Inhibitors from 2021 to 2026.
Chapter 3, the PD-1/PD-L1 Checkpoint Inhibitors competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PD-1/PD-L1 Checkpoint Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and PD-1/PD-L1 Checkpoint Inhibitors market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of PD-1/PD-L1 Checkpoint Inhibitors.
Chapter 14 and 15, to describe PD-1/PD-L1 Checkpoint Inhibitors sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 PD-1 Inhibitors
- 1.3.3 PD-L1 Inhibitors
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Squamous Cell Skin Cancer
- 1.4.3 Non-small Cell Lung Cancer
- 1.4.4 Melanoma
- 1.4.5 Gastric Cancer
- 1.4.6 Other
- 1.5 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size & Forecast
- 1.5.1 Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (2021-2032)
- 1.5.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Bristol Myers Squibb
- 2.1.1 Bristol Myers Squibb Details
- 2.1.2 Bristol Myers Squibb Major Business
- 2.1.3 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product and Services
- 2.1.4 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Bristol Myers Squibb Recent Developments/Updates
- 2.2 Merck
- 2.2.1 Merck Details
- 2.2.2 Merck Major Business
- 2.2.3 Merck PD-1/PD-L1 Checkpoint Inhibitors Product and Services
- 2.2.4 Merck PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Merck Recent Developments/Updates
- 2.3 Regeneron Pharmaceuticals
- 2.3.1 Regeneron Pharmaceuticals Details
- 2.3.2 Regeneron Pharmaceuticals Major Business
- 2.3.3 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product and Services
- 2.3.4 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Regeneron Pharmaceuticals Recent Developments/Updates
- 2.4 Roche
- 2.4.1 Roche Details
- 2.4.2 Roche Major Business
- 2.4.3 Roche PD-1/PD-L1 Checkpoint Inhibitors Product and Services
- 2.4.4 Roche PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Roche Recent Developments/Updates
- 2.5 Pfizer
- 2.5.1 Pfizer Details
- 2.5.2 Pfizer Major Business
- 2.5.3 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product and Services
- 2.5.4 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Pfizer Recent Developments/Updates
- 2.6 AstraZeneca
- 2.6.1 AstraZeneca Details
- 2.6.2 AstraZeneca Major Business
- 2.6.3 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product and Services
- 2.6.4 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 AstraZeneca Recent Developments/Updates
- 2.7 Hengrui Pharmaceuticals
- 2.7.1 Hengrui Pharmaceuticals Details
- 2.7.2 Hengrui Pharmaceuticals Major Business
- 2.7.3 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product and Services
- 2.7.4 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Hengrui Pharmaceuticals Recent Developments/Updates
- 2.8 Junshi Biosciences
- 2.8.1 Junshi Biosciences Details
- 2.8.2 Junshi Biosciences Major Business
- 2.8.3 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product and Services
- 2.8.4 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Junshi Biosciences Recent Developments/Updates
3 Competitive Environment: PD-1/PD-L1 Checkpoint Inhibitors by Manufacturer
- 3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Manufacturer (2021-2026)
- 3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of PD-1/PD-L1 Checkpoint Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 PD-1/PD-L1 Checkpoint Inhibitors Manufacturer Market Share in 2025
- 3.4.3 Top 6 PD-1/PD-L1 Checkpoint Inhibitors Manufacturer Market Share in 2025
- 3.5 PD-1/PD-L1 Checkpoint Inhibitors Market: Overall Company Footprint Analysis
- 3.5.1 PD-1/PD-L1 Checkpoint Inhibitors Market: Region Footprint
- 3.5.2 PD-1/PD-L1 Checkpoint Inhibitors Market: Company Product Type Footprint
- 3.5.3 PD-1/PD-L1 Checkpoint Inhibitors Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region
- 4.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Region (2021-2032)
- 4.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Region (2021-2032)
- 4.1.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Region (2021-2032)
- 4.2 North America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
- 4.3 Europe PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
- 4.4 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
- 4.5 South America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
- 4.6 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
- 5.2 Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Type (2021-2032)
- 5.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
- 6.2 Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Application (2021-2032)
- 6.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Application (2021-2032)
7 North America
- 7.1 North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
- 7.2 North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
- 7.3 North America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country
- 7.3.1 North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2032)
- 7.3.2 North America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
- 8.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
- 8.3 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country
- 8.3.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2032)
- 8.3.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region
- 9.3.1 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
- 10.2 South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
- 10.3 South America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country
- 10.3.1 South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2032)
- 10.3.2 South America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country
- 11.3.1 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 PD-1/PD-L1 Checkpoint Inhibitors Market Drivers
- 12.2 PD-1/PD-L1 Checkpoint Inhibitors Market Restraints
- 12.3 PD-1/PD-L1 Checkpoint Inhibitors Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of PD-1/PD-L1 Checkpoint Inhibitors and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of PD-1/PD-L1 Checkpoint Inhibitors
- 13.3 PD-1/PD-L1 Checkpoint Inhibitors Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 PD-1/PD-L1 Checkpoint Inhibitors Typical Distributors
- 14.3 PD-1/PD-L1 Checkpoint Inhibitors Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on PD-1/PD-L1 Checkpoint Inhibitors. Industry analysis & Market Report on PD-1/PD-L1 Checkpoint Inhibitors is a syndicated market report, published as Global PD-1/PD-L1 Checkpoint Inhibitors Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of PD-1/PD-L1 Checkpoint Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
